United States Food and Drug Administration Drug Approval Summary
Martin H. Cohen(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), W. David McGuinn(United States Food and Drug Administration), Chenyi Liang(United States Food and Drug Administration), Richard T. Lostritto(United States Food and Drug Administration), Atiqur Rahman(Jamia Millia Islamia), Gang Chen(Tongji Hospital), Grant A. Williams(United States Food and Drug Administration), Rajeshwari Sridhara(Center for Drug Evaluation and Research), David E. Morse(United States Food and Drug Administration), Sophia Abraham(United States Food and Drug Administration), Amy Baird(United States Food and Drug Administration)
Cited by 500
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k